Literature DB >> 20660099

Alterations of bone marrow-derived endothelial progenitor cells following acute pulmonary embolism in mice.

Jun Wan1, Li-Jin Lu, Ran Miao, Jie Liu, Xiao-Xue Xu, Ting Yang, Qing-Hua Hu, Jun Wang, Chen Wang.   

Abstract

Pulmonary embolism (PE) is a common, lethal, ischemic disease. PE-induced endothelium injury plays a critical role in the pathophysiological consequences of PE. Endothelial progenitor cells (EPCs) can be mobilized from the bone marrow to enter circulation and play important roles in repair of damaged endothelium. However, it is not yet known if EPC mobilization results from PE. The alterations of the quantity and function of bone marrow-derived EPCs were detected in acute pulmonary embolism (APE) events in mice, and the possible role of the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) pathway in those alterations was explored. APE models were established by injection of autologous thrombi into the right jugular vein of C57BL/6 mice. Mice were divided into sham and experimental groups including one hour (1H), one day (1D) and two day (2D) groups after injection. The results showed that in the APE 1D group, the thrombi were easily found in the large or medium pulmonary vessel. And CD133(+) or CD34(+) cells in bone marrow increased significantly, while CD133(+)/vascular endothelial growth factor receptor 2(+) EPCs decreased. After seven days in culture, the abilities of incorporation into a vascular network, adhesion to fibronectin, migration and proliferation of bone marrow-derived EPCs in the APE 1D group increased significantly. The mRNA and protein expression levels of eNOS in EPCs increased in the APE 1D group. Treatment of EPCs with N(G)-nitro-L-arginine methyl ester inhibited functional alterations induced by APE. The results suggested that APE events stimulate the mobilization of EPCs from bone marrow, and enhance their functions. The eNOS/NO pathway may be involved in this process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660099     DOI: 10.1258/ebm.2010.010057

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  6 in total

1.  JANEX-1 improves acute pulmonary embolism through VEGF and FAK in pulmonary artery smooth muscle cells.

Authors:  Longfei Pan; Zhuo Peng; Ruipeng Zhang; Rui Zhang; Dean Liang; Heming Chen; Hongyan Tian
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-15

2.  Angiogenic Factor AGGF1-Primed Endothelial Progenitor Cells Repair Vascular Defect in Diabetic Mice.

Authors:  Yufeng Yao; Yong Li; Qixue Song; Changqin Hu; Wen Xie; Chengqi Xu; Qiuyun Chen; Qing K Wang
Journal:  Diabetes       Date:  2019-05-15       Impact factor: 9.461

3.  Gene Expression Profiling of Pulmonary Artery in a Rabbit Model of Pulmonary Thromboembolism.

Authors:  Zhiyuan Tang; Xudong Wang; Jianfei Huang; Xiaoyu Zhou; Hao Xie; Qilin Zhu; Minjie Huang; Songshi Ni
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

4.  Bioinformatics-based study to detect chemical compounds that show potential as treatments for pulmonary thromboembolism.

Authors:  Keyu Sun; Zichen Xie; Jiqin Wang; Meirong Ling; Yanyan Li; Chao Qiu
Journal:  Int J Mol Med       Date:  2018-11-12       Impact factor: 4.101

Review 5.  Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension.

Authors:  Andrei A Karpov; Dariya D Vaulina; Sergey S Smirnov; Olga M Moiseeva; Michael M Galagudza
Journal:  Heliyon       Date:  2022-02-24

6.  Statins, HMG-CoA Reductase Inhibitors, Improve Neovascularization by Increasing the Expression Density of CXCR4 in Endothelial Progenitor Cells.

Authors:  Kuang-Hsing Chiang; Wan-Li Cheng; Chun-Ming Shih; Yi-Wen Lin; Nai-Wen Tsao; Yung-Ta Kao; Chih-Ting Lin; Shinn-Chih Wu; Chun-Yao Huang; Feng-Yen Lin
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.